Log In
Print
BCIQ
Print
Print this Print this
 

AZD1775, MK-1775

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionWEE1 tyrosine kinase (WEE1) inhibitor
Molecular Target WEE1 tyrosine kinase (WEE1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationOvarian cancer
Indication DetailsTreat epithelial ovarian cancer
Regulatory Designation

Partner

AstraZeneca plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today